Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.1.37 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Dina Javidjam and 7 co-authors. Institution: Division of Ophthalmology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Major MEDLINE topics: Duloxetine Hydrochloride, Aniridia, Gene Expression Profiling, Corneal Diseases. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Aniridia-associated keratopathy (AAK) leads to loss of corneal transparency because of epithelial, inflammatory, and pathological vascular changes. Here, we sought to understand this process at the transcriptomic level while evaluating an experimental pharmacotherapy for potential modulatory effects.
Method
17 Pax6+/- Small-eye (Sey) heterozygous mice with p.Gly208* Pax6 mutation and 10 wild-type 129S1/SvImJ mice at four months of age were examined to identify dysregulated genes and pathways in established AAK. We next evaluated the potential efficacy of 10 µM duloxetine administered as eye drops twice daily for 90 days, assessing outcomes at the transcriptomic level via microarray and protein level with Western blot and immunostaining.
Results
Transcriptomic analysis of the cornea revealed enrichment of Ccl21 gene family members associated with lymphangiogenesis, along with upregulation of genes involved in inflammation, cell adhesion, differentiation, motility, and keratinization, and downregulation of drug metabolism with significantly dysregulated genes emerging as potential therapeutic targets, including Gpha2, Chrnb3, Epgn, Cnfn, kallikreins and inflammation mediators Il18r1 and classical complement factors. Duloxetine therapy failed to regress AAK in adult corneas; however, transcriptomic profiling indicated duloxetine suppressed inflammatory genes and promoted anti-inflammatory and protective activity while modulating drug metabolism, suggesting potential beneficial effects in the cornea.
Conclusions
Transcriptomics reveals multiple unexplored pathways and genes altered in the AAK mouse model. Although clinical results with duloxetine are promising, our current regimen and delivery method did not improve established disease. Duloxetine's therapeutic potential requires further study.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Division of Ophthalmology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- INSERM UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.
- Université Paris Cité, Paris, France.
- Service de Pharmacie, Hôpital Universitaire Necker - Enfants Malades, APHP, Paris, France.
- Université Paris Cité, INSERM UMRS 1144, Faculté de Pharmacie, Paris, France.
- Ophthalmology Department, Hôpital Universitaire Necker - Enfants Malades, Paris, France.
Cite
APA
Javidjam, D., Moustardas, P., Dashti, A., Aberdam, D., Schweitzer-Chaput, A., Cisternino, S., Bremond-Gignac, D., & Lagali, N. (2026). Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.1.37
Vancouver
Javidjam D, Moustardas P, Dashti A, Aberdam D, Schweitzer-Chaput A, Cisternino S, et al. Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.1.37
BibTeX
@article{Javidjam2026,
author = {Javidjam, Dina and Moustardas, Petros and Dashti, Ava and Aberdam, Daniel and Schweitzer-Chaput, Arnaud and Cisternino, Salvatore and Bremond-Gignac, Dominique and Lagali, Neil},
title = {Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.1.37}
}
EUVIMED